Press Releases

Feb 25, 2019

Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
Feb 11, 2019

Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price

* This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients
Feb 7, 2019

Sanofi delivers 2018 business EPS growth of 5.1% at CER
- Video 1
- Photos 4
Feb 6, 2019

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

- First medicine approved in the U.S. specifically for the treatment of aTTP, a rare blood-clotting disorder
Jan 23, 2019

FDA approves use of 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) in children as young as 6 months of age

- The 0.5 mL dose is now approved for use in children 6 months through 35 months of age

Show per page

Print
Email page
RSS